MDS 2022 | Early identification of suboptimal PD control to improve care

Eric Freire-Alvarez, MD, University General Hospital of Elche, Elche, Spain, talks about the importance of early identification of Parkinson’s disease patients uncontrolled on oral medications. Numerous studies over the last years have reinforced the idea that starting treatment at an early disease stage can improve the patient’s quality of life. Therefore, identifying early motor and non-motor fluctuations can benefit the management of patients. Deep brain stimulation, levodopa‐carbidopa intestinal gel with or without entacapone, and subcutaneous apomorphine infusion are device‐aided therapies currently available to maintain symptom control. In the future, continuous subcutaneous levodopa infusion is hoped to expand the therapeutic options. This interview took place at the 2022 International Congress of Parkinson’s Disease and Movement Disorders in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.